Dynavax to Present at 37th Annual J.P. Morgan Healthcare Conference
January 03 2019 - 04:05PM
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated
biopharmaceutical company focused on discovering and developing
novel vaccines and immuno-oncology therapeutics, today announced
that Eddie Gray, Chief Executive Officer, will present at the 37th
Annual J.P. Morgan Healthcare Conference on Thursday, January 10,
at 9 am PT.
The presentation will be webcast and may be accessed at the
“Events & Presentations” section of the Company’s website at
http://investors.dynavax.com/events-presentations.
About Dynavax Dynavax is a
fully-integrated biopharmaceutical company focused on leveraging
the power of the body's innate and adaptive immune responses
through toll-like receptor (TLR)
stimulation. Dynavax discovers and develops novel
vaccines and immuno-oncology therapeutics. The Company launched its
first commercial product, HEPLISAV-B® [Hepatitis B Vaccine
(Recombinant), Adjuvanted], in February 2018, following
U.S. FDA approval for prevention of infection caused by
all known subtypes of hepatitis B virus in adults age 18 years and
older. Dynavax's lead immunotherapy product, SD-101, is
an investigational cancer immunotherapeutic currently being
evaluated in Phase 1/2 studies and its second cancer
immunotherapeutic, DV281, is in Phase 1 development. For more
information, visit www.dynavax.com.
ContactHeather Rowe Vice President, Investor
Relations & Corporate Communications 510-665-7269
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2023 to Mar 2024